|
Adrenal Gland Pheochromocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To define the molecular changes occurring in endocrine tumours, we have analysed three human endocrine tumours established in our laboratory: BON, a functioning carcinoid tumour from the pancreas; SIM, a nonfunctioning carcinoid of the ileum; and STAN, a pheochromocytoma.
|
7952399 |
1994 |
|
Adult Classical Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent super-resolution fluorescence microscopy (3D-Structured Illumination Microscopy, 3D-SIM) studies have revealed significantly altered nuclear organization between normal lymphocyte nuclei and those of classical Hodgkin's Lymphoma.
|
30327804 |
2018 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Single-minded 2 (Sim2), a transcriptional repressor, is reportedly involved in diseases that impair learning and memory, such as Down syndrome (DS) and Alzheimer's disease.
|
25319570 |
2015 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
SIM2 and RUNX1 were comparable between groups, while BACH1 was significantly reduced in DS, and ERG was increased in DS and AD as compared to controls.
|
15068237 |
2003 |
|
Benign Prostatic Hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In a matched set of tissues of Benign Prostatic Hyperplasia (BPH) and prostate carcinomas, sim2-s expression was detected in the BPH.
|
12530058 |
2003 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Brain Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In present study, we found that SIM2-s was expressed in glioma tissues as well as in glioblastoma (GBM) cell lines but not in other brain tumors or normal cortex.
|
20448453 |
2010 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Consistent with its role as a transcriptional repressor, SIM2s directly decreased expression of matrix metalloprotease-3, a known mediator of breast cancer metastasis.
|
16840439 |
2007 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Cross-talk between SIM2s and NFκB regulates cyclooxygenase 2 expression in breast cancer.
|
31783895 |
2019 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We have previously shown that Singleminded-2s (SIM2s), a member of the basic helix-loop-helix Per-Arnt-Sim (bHLH/PAS) family of transcription factors, is downregulated in breast cancer samples and has tumor suppressor activity.
|
19169276 |
2009 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Initial analysis of the effect loss of SIM2s has on replication stress resolution was conducted using DNA combing assays in established breast cancer cell lines.
|
31775907 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Additionally, knockdown of SIM2s in MCF-7 breast cancer cells contributed to an epithelial-mesenchymal transition (EMT) and increased tumorigenesis.
|
18160708 |
2008 |
|
Carcinoid Tumor
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
To define the molecular changes occurring in endocrine tumours, we have analysed three human endocrine tumours established in our laboratory: BON, a functioning carcinoid tumour from the pancreas; SIM, a nonfunctioning carcinoid of the ileum; and STAN, a pheochromocytoma.
|
7952399 |
1994 |
|
Carcinoid Tumor
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The differential polymerase chain reaction procedure was used to detect genomic amplification in DNA samples from human endocrine tumor cell lines (BON, SIM, STAN) and from paraffin-embedded samples of carcinoid tumors.
|
1353638 |
1992 |
|
Carcinoid tumor no ICD-O subtype
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To define the molecular changes occurring in endocrine tumours, we have analysed three human endocrine tumours established in our laboratory: BON, a functioning carcinoid tumour from the pancreas; SIM, a nonfunctioning carcinoid of the ileum; and STAN, a pheochromocytoma.
|
7952399 |
1994 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Isoform-specific expression of SIM2 short-form (SIM2-s) was seen selectively in colon, prostate, and pancreatic carcinomas but not in breast, lung, or ovarian carcinomas nor in most normal tissues.
|
12676991 |
2003 |
|
Cervical Squamous Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SIM2 knockdown in CvSCC cell lines showed resistance to hypoxia with increased expression of HIF1A and its target genes.
|
29109451 |
2017 |
|
Classical Hodgkin's Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent super-resolution fluorescence microscopy (3D-Structured Illumination Microscopy, 3D-SIM) studies have revealed significantly altered nuclear organization between normal lymphocyte nuclei and those of classical Hodgkin's Lymphoma.
|
30327804 |
2018 |
|
Cleft Palate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Craniofacial abnormalities resulting from targeted disruption of the murine Sim2 gene.
|
12203729 |
2002 |
|
Cleft palate, isolated
|
0.300 |
Biomarker
|
disease |
CTD_human |
Craniofacial abnormalities resulting from targeted disruption of the murine Sim2 gene.
|
12203729 |
2002 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Antisense inhibition of SIM2-s expression in a colon cancer cell line caused inhibition of gene expression, growth inhibition, and apoptosis.
|
12676991 |
2003 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Antisense inhibition of SIM2-s in a RKO-derived colon carcinoma cell line causes growth inhibition, apoptosis, and inhibition of tumor growth in a nude mouse tumoriginicity model.
|
16129820 |
2005 |
|
Colonic Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Stage-specific expression of the sim2-s protein was seen in normal matched paraffin sections of the colon tumors.
|
12530058 |
2003 |
|
Colonic Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
A Down's syndrome associated gene, Single Minded 2 gene short form (SIM2-s), is specifically expressed in colon tumors but not in the normal colon.
|
16129820 |
2005 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The SIM-AIMS assay could also detect WT and V600E BRAF in CRC specimens, but the measured levels of both targets were lower than those determined by MRM assay.
|
27497007 |
2016 |